Why is Rapport Therapeutics stock surging 31% today?

Jones Trading raised its price target for Rapport Therapeutics (RAPP) to $82 from $50, maintaining a Buy rating. The firm cited positive clinical trial results for the company’s RAP-219 drug candidate in FOS and BPM indications. The stock currently trades at $29.37, giving the company a market capitalization of $1.41 billion. Analysts have varied price targets and ratings for RAPP, with a consensus Strong Buy rating.

RAPP stock initially rose but later tempered gains due to concerns over higher discontinuation rates in a bipolar mania study. Analysts at H.C. Wainwright and Raymond James raised their price targets to $66 and $86 respectively, while Wells Fargo maintained an Overweight rating with a $51 target. Retail traders on Stocktwits reacted bullishly, with some suggesting the company is a potential buyout candidate. The stock is down 3% year-to-date.

Guggenheim raised its price target on Rapport Therapeutics (RAPP) to $70 from $65, citing positive Phase 2 trial results for bipolar mania. The trial met primary and secondary endpoints, with a 3.1-point placebo-adjusted YMRS reduction. Guggenheim increased its success probability to 65% and adjusted its expected launch to 2030. The stock is currently trading at $30.20, with a Strong Buy consensus among analysts.

Raymond James raised its price target for Rapport Therapeutics (RAPP) to $86 from $75, citing positive bipolar disorder trial results. The stock trades at $29.31, with a market cap of $1.37B. Multiple analysts maintain Buy ratings, highlighting the drug's potential and strong balance sheet.

Truist Securities reiterated a Buy rating and $56.00 price target for Rapport Therapeutics (RAPP) after positive clinical trial results for RAP-219 in bipolar mania. The stock is currently trading at $29.74, with a Wall Street consensus of Strong Buy and price targets ranging from $50 to $80. Analysts noted consistent efficacy, a clean safety profile, and planned Phase 3 enhancements. The company maintains a strong financial position with a current ratio of 15.72.

TD Cowen reiterated a Buy rating on Rapport Therapeutics (RAPP) after positive Phase II trial results for RAP-219 in bipolar mania. The trial met primary and secondary endpoints, with a 3.1 point placebo-adjusted improvement on the Young Mania Rating Scale. TD Cowen estimates peak sales of $2.9 billion for RAP-219 and values RAPP at $60 per share, citing strong financial health and pipeline potential.